ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).

Louise Emmett Shalini SubramaniamAnthony M JoshuaMegan CrumbakerAndrew MartinAlison Y ZhangNisha RanaAilsa LangfordJenna MitchellSonia YipRoslyn FrancisMichael S HofmanShahneen SandhuArun A AzadCraig GedyeMargaret McJannettMartin R StocklerIan D Davisnull null

Published in: BJU international (2021)

The combination of 177 Lu-PSMA-617 and enzalutamide may be synergistic. ENZA-p will determine the safety and efficacy of the combination in addition to developing predictive and prognostic biomarkers to better guide treatment decisions.

Keyphrases

prostate cancer
small cell lung cancer
pet ct
squamous cell carcinoma
randomized controlled trial
study protocol
clinical trial
phase iii
open label
phase ii
pet imaging
cancer therapy
newly diagnosed
smoking cessation